Novo Nordisk or Eli Lilly: which weight loss giant is the best investment? Novo Nordisk or Eli Lilly: which weight loss giant is the best investment? Novo Nordisk or Eli Lilly: which weight loss giant is the best investment?

Novo Nordisk or Eli Lilly: which weight loss giant is the best investment?

Oskar Barner Bernhardtsen

Investment strategist

Novo Nordisk is the most commonly-held non-US stock among Saxo's 1.2 million global customers and, for most, a fruitful investment to date. Since 2021, the Danish company’s stock has risen by more than 300% - and is up 25% year to date.

This dizzying increase can be mainly attributed to the popularity of new weight loss medications, produced most notably by Novo Nordisk (semaglutide drugs Wegovy and Ozempic) and US pharmaceutical giant Eli Lilly (tirzepatide drugs Zepbound and Mounjaro).

Saxo believes that, given ongoing supply constraints and expected growth in the obesity treatment industry, both companies are likely to generate good returns for years to come.

But which of the major weight loss giants is actually the most attractive to invest in? Alternatively, should investors seek exposure to both companies to ensure they capture the broader growth trend in weight loss medication?

As seen in the graphs below, Eli Lilly (orange) is expected to grow their revenue significantly more than Novo Nordisk (blue) in the coming years, possibly due to the US company being further along in their research into Alzheimer's treatments.

Novo Lilly 11

Additionally, Eli Lilly took longer to get their weight loss medication, Zepbound, approved and launched compared to Novo Nordisk. Zepbound is generally considered a more effective medication with higher weight loss compared to Wegovy, and it is therefore expected that Eli Lilly will take significant market share from Novo Nordisk in the coming years.

As shown in the graph below, Novo Nordisk sold their first doses of Wegovy at the beginning of 2021. In mid-2021, Wegovy was approved in the USA, but until the end of 2022, sales growth in Wegovy was relatively modest. This may be because Novo Nordisk prioritised the production of Ozempic over Wegovy.

However, comparing Wegovy (blue) to Zepbound’s (orange) growth curve (approved for sale in the USA at the end of 2023), one can clearly see the difference in launch speed and aggressiveness.

Novo Lilly 22

In other words, Wegovy/Ozempic remains the market leader in weight loss medication, but Eli Lilly is quickly catching up to Novo Nordisk's sales figures and is expected to overtake Novo Nordisk within the next 12 months.

The market also expects Eli Lilly to surpass Novo Nordisk in terms of profit in the coming years. By 2028, Eli Lilly is expected to grow profits to USD 36.5 billion, while Novo Nordisk is expected to deliver around USD 26 billion in profit.

Therefore, it seems that Novo Nordisk will face significant competition from Eli Lilly in the coming years. Both companies are expected to grow strongly, but Eli Lilly is expected to grow significantly more than Novo Nordisk. However, Eli Lilly's stock is also significantly higher valued compared to Novo Nordisk, relative to the expected 2024 earnings.

As shown in the graph below, an investor today pays about 39 times the expected 2024 earnings for Novo Nordisk (blue), but 56 times the expected 2024 earnings for Eli Lilly (orange). However, looking at the expected earnings for 2028 relative to the companies' market value today, both trade at 22 times the expected 2028 earnings.

PE ratio measured by expected future earnings Source Koyfin 1

Novo Nordisk seems undervalued compared to Eli Lilly when looking at expectations for 2024. However, when considering the higher earnings growth expected at Eli Lilly compared to Novo Nordisk, the two stocks are currently valued at roughly the same level.

Therefore, we believe it makes sense for investors who are heavily invested in Novo Nordisk to take a closer look at Eli Lilly. The expectation is that the two companies will share the market for weight loss medications between them, and any new growth in Alzheimer's treatments will likely also be shared.

If an investor wants broad exposure to both weight loss medication and Alzheimer's treatments, they should consider whether there is room for both stocks in their portfolio.

Quarterly Outlook 2024 Q3

Sandcastle economics

01 / 05

  • Macro: Sandcastle economics

    Invest wisely in Q3 2024: Discover SaxoStrats' insights on navigating a stable yet fragile global economy.

    Read article
  • Bonds: What to do until inflation stabilises

    Discover strategies for managing bonds as US and European yields remain rangebound due to uncertain inflation and evolving monetary policies.

    Read article
  • Equities: Are we blowing bubbles again

    Explore key trends and opportunities in European equities and electrification theme as market dynamics echo 2021's rally.

    Read article
  • FX: Risk-on currencies to surge against havens

    Explore the outlook for USD, AUD, NZD, and EM carry trades as risk-on currencies are set to outperform in Q3 2024.

    Read article
  • Commodities: Energy and grains in focus as metals pause

    Energy and grains to shine as metals pause. Discover key trends and market drivers for commodities in Q3 2024.

    Read article
Disclaimer

Saxo Capital Markets (Australia) Limited prepares and distributes information/research produced within the Saxo Bank Group for informational purposes only. In addition to the disclaimer below, if any general advice is provided, such advice does not take into account your individual objectives, financial situation or needs. You should consider the appropriateness of trading any financial instrument as trading can result in losses that exceed your initial investment. Please refer to our Analysis Disclaimer, and our Financial Services Guide and Product Disclosure Statement. All legal documentation and disclaimers can be found at https://www.home.saxo/en-au/legal/.

The Saxo Bank Group entities each provide execution-only service. Access and use of Saxo News & Research and any Saxo Bank Group website are subject to (i) the Terms of Use; (ii) the full Disclaimer; and (iii) the Risk Warning in addition (where relevant) to the terms governing the use of the website of a member of the Saxo Bank Group.

Saxo News & Research is provided for informational purposes, does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. No representation or warranty is given as to the accuracy or completeness of this information. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. No Saxo Bank Group entity shall be liable for any losses that you may sustain as a result of any investment decision made in reliance on information on Saxo News & Research.

To the extent that any content is construed as investment research, such content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication.

None of the information contained here constitutes an offer to purchase or sell a financial instrument, or to make any investments.Saxo Capital Markets does not take into account your personal investment objectives or financial situation and makes no representation and assumes no liability as to the accuracy or completeness of the information nor for any loss arising from any investment made in reliance of this presentation. Any opinions made are subject to change and may be personal to the author. These may not necessarily reflect the opinion of Saxo Capital Markets or its affiliates.

Please read our disclaimers:
- Full Disclaimer (https://www.home.saxo/en-au/legal/disclaimer/saxo-disclaimer)
- Analysis Disclaimer (https://www.home.saxo/en-au/legal/analysis-disclaimer/saxo-analysis-disclaimer)
- Notification on Non-Independent Investment Research (https://www.home.saxo/legal/niird/notification)

Saxo Capital Markets (Australia) Limited
Suite 1, Level 14, 9 Castlereagh St
Sydney NSW 2000
Australia

Contact Saxo

Select region

Australia
Australia

The Saxo trading platform has received numerous awards and recognition. For details of these awards and information on awards visit www.home.saxo/en-au/about-us/awards

Saxo Capital Markets (Australia) Limited ABN 32 110 128 286 AFSL 280372 (‘Saxo’ or ‘Saxo Capital Markets’) is a wholly owned subsidiary of Saxo Bank A/S, headquartered in Denmark. Please refer to our General Business Terms, Financial Services Guide, Product Disclosure Statement and Target Market Determination to consider whether acquiring or continuing to hold financial products is suitable for you, prior to opening an account and investing in a financial product.

Trading in financial instruments carries various risks, and is not suitable for all investors. Please seek expert advice, and always ensure that you fully understand these risks before trading. Saxo Capital Markets does not provide ‘personal’ financial product advice, any information available on this website is ‘general’ in nature and for informational purposes only. Saxo Capital Markets does not take into account an individual’s needs, objectives or financial situation. The Target Market Determination should assist you in determining whether any of the products or services we offer are likely to be consistent with your objectives, financial situation and needs.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the US and other countries. AppStore is a service mark of Apple Inc.

The information or the products and services referred to on this website may be accessed worldwide, however is only intended for distribution to and use by recipients located in countries where such use does not constitute a violation of applicable legislation or regulations. Products and Services offered on this website is not intended for residents of the United States and Japan.

Please click here to view our full disclaimer.